Co-sponsored by C-Path and the FDA, this annual event serves as PSTC’s foremost venue for presentation and in depth discussion of our current work in safety biomarker qualification. The meeting is attended by many individuals from the FDA and each of the 19 member companies. Highlights of this year’s meeting included sessions on Translational Dialogue, Biosignatures Approaches and Building Successful Drug Development Programs Through Biomarkers.
Previous meetings have focused on other cutting edge subjects in the field, including miRNA, the Impact and Promise of Biomarkers, Statistical Methods for Biomarker Performance Analysis, and Translational Regulatory Strategy. The input from experts within the FDA and industry brings high value to these meetings and encourages open dialogue on how to achieve success.